(RTTNews) - XenoPort (XNPT) slid in pre-market trading, after announcing top-line results from phase 2 clinical trial of XP19986 as a treatment for symptoms of gastroesophageal reflux disease.
The stock was down $3.24 just before 8:40 am ET, slipping to $15.67. If pre-market losses hold, the stock will open at its lowest level since February 2006.
XenoPort revealed top-line results from a Phase 2 clinical trial that examined the ability of XP19986 extended-release tablets to reduce symptoms experienced by subjects with gastroesophageal reflux disease, or GERD.
According to the company, the primary analysis comparing XP19986 to placebo did not reach statistical significance. However, pre-defined subgroup analyses showed statistically significant benefits of XP19986 on a number of important parameters. The company further noted that XP19986 was generally well tolerated at all dose levels.
For comments and feedback: contact editorial@rttnews.com
Copyright(c) 2008 RealTimeTraders.com, Inc. All Rights Reserved
